Clinical Trials Logo

Depressive Episode clinical trials

View clinical trials related to Depressive Episode.

Filter by:

NCT ID: NCT06152705 Not yet recruiting - Depression Clinical Trials

Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

In this triple-blind randomized controlled trial, we ask if targeting intermittent theta burst stimulation (iTBS) based on individual resting state connectivity improves treatment outcomes in major depressive disorder (MDD). For the trial, we will recruit 210 patients with major depressive disorder. Each patient will undergo a 30-40-minute MRI scan, after which they will receive a 6-week standard iTBS treatment. Participants will be randomized to receive iTBS either to the standard neuronavigated target (a technique for treatment location targeting, based on group-average connectivity) or to a personalized connectivity-guided target selected based on individual functional connectivity scans. The main outcome of this trial is response rate as determined by ≥ 50% reduction in Grid HRSD-17 scores. Secondary outcomes include remission rate, change in depression, anxiety and anhedonia symptoms, quality of life, and biological measures of heart rate variability, objective sleep measures and daily activity as a proxy of anhedonia - defined as a reduced ability to experience pleasure.

NCT ID: NCT05910775 Not yet recruiting - Depressive Episode Clinical Trials

Role Of Non-Specific Effects in The Treatment of Depression With Esketamine

Start date: November 2023
Phase: N/A
Study type: Interventional

The investigators aim to examine the magnitude of non-specific effects in the treatment of depressive episodes with esketamine, by providing patients in the intervention group with a pretreatment presentation and post-treatment follow up session, to assess whether nonspecific effects can be used effectively to improve the effectiveness of treatment with esketamine.

NCT ID: NCT05708222 Recruiting - Depression Clinical Trials

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Start date: September 1, 2022
Study type: Observational

The objective of this study is to collect data to finalize the development of MEB-001 softward as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the algorithms to match the patient's demographic and clinical information, and the objective physiological signals (i.e., electroencephalogram (EEG) and electrocardiogram (ECG)) recorded during PSG with the diagnosis of cMDE performed through the MINI neuropsychiatric evaluation.

NCT ID: NCT05701345 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder

Start date: March 9, 2023
Phase: N/A
Study type: Interventional

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks. The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.

NCT ID: NCT05691647 Recruiting - Depressive Episode Clinical Trials

Chronotherapy for Depressive Episodes

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

Evidence-based treatments for depression, such as antidepressive medication, usually have a latency of 4 to 6 weeks before they achieve a therapeutic effect. Chronotherapy is a group of non-pharmacological interventions that presumably act on the circadian system to achieve a rapid-onset clinical effect and better long-term effects and has been shown efficient to improve depressive symptoms. Interventions include sleep deprivation, sleep-phase advancement and stabilization, and light therapy. There are few studies testing the effectiveness of combining these three chronotherapeutic techniques in the initial phase of treatment of depression in a secondary mental health care outpatient clinic. The investigators aim to test the effects and safety of chronotherapy in addition to TAU compared to TAU alone, with the primary outcome being self-reported depressive symptoms at 1 week following randomization. The study is a randomized controlled trial with 76 patients with a depressive episode who initiate outpatient treatment at Nidaros DPS, St. Olavs University Hospital. Participants will be allocated 1:1 to either chronotherapy + treatment as usual (TAU) or to TAU alone.

NCT ID: NCT05686408 Active, not recruiting - Depression Clinical Trials

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Start date: March 2, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).

NCT ID: NCT05683028 Recruiting - Depressive Episode Clinical Trials

RCT for Electroconvulsive Treatment Followed by Cognitive Control Training

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high. Cognitive side effects of ECT, such as reduced cognitive control, might trigger mechanisms that increase relapse in patients. As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).

NCT ID: NCT05678907 Not yet recruiting - Depressive Episode Clinical Trials

Predictive Value of the DD4 Questionnaire on Depressive Relapse After Hospitalization.

Start date: January 2, 2023
Study type: Observational

This is a prospective, longitudinal, single-center observational study of data from the medical records of patients hospitalized after a characterized depressive episode and reviewed three months after hospital discharge, as part of a normally scheduled evaluation.

NCT ID: NCT05654948 Recruiting - Depressive Episode Clinical Trials

Characterisation of Fundamental Decision Making in People Suffering From a Characterised Depressive Episode

Start date: February 9, 2023
Study type: Observational

The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.

NCT ID: NCT05641623 Recruiting - Depression Clinical Trials

OSU6162 as add-on in SSRI/SNRI-resistant Depression

Start date: April 21, 2022
Phase: Phase 2
Study type: Interventional

This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that have not responded to treatment with an SSRI/SNRI per se for at least 6 weeks. The study will last for 6 weeks, after which those not having responded will leave the trial and those having responded will be offered to continue treatment without unblinding for another 4 weeks. While assessment of the efficacy and safety of OSU6162 is the main objective of this study, possible differences between the two treatment groups with respect to a number of biomarkers in serum will also be explored. Multicenter trial: Multiple sites four Gothenburg, Lund, Stockholm and Uppsala.